Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 05, 2022 12:11pm
131 Views
Post# 34802154

RE:RE:RE:The REAL reason THTX stock price is declining.

RE:RE:RE:The REAL reason THTX stock price is declining.

It's the issue I mentioned to IR about how the inability to engage a larger subset of investors in a convincing thesis, or to explain why their science is worthy of attention even if the news flow is slow, has created a one-way market situation.  The problem becomes a nightmare for shareholders if only a few investors bail and send it down, whether an advisor change or boredom.  It's an effort, but you have to do it if public, to proactively create a case with factual backup and not just saying "we feel positive" or "everything looks great".  Explain the whys behind that with more detail if you do feel that way. 


I recall them saying it would soon change and there would be a slew of information released rather frequently as spring went in to summer and fall.  So far, that hasn't been the case.  They still have summer and fall, so hopefully that changes. Market needs some serious demand amplifiers and science data. The discourse has not seemed to really change much over the last year. Maybe they need another LSA KOL type event around Sort1 and POC if they get there. 



Bucknelly21 wrote: Agree with all of this, not to mention they keep everyone in the dark almost religiously. They clearly don't understand how to engage and create an investment thesis and never have, which is why the people that have owned thera so long constantly re-afirm this. Only a homerun in oncology will be able to make a difference at this point

 

<< Previous
Bullboard Posts
Next >>